Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Theragen Bio Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows that the company is managing multiple patent applications simultaneously across different technical classifications.
EMCH, GREGORY S is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This means that EMCH, GREGORY S is responsible for 1 of the 2 pending office actions. The use of 2 distinct art units indicates that the subject matter spans different technical groups within the patent office, requiring a versatile prosecution approach.
For a practitioner, the presence of 2 distinct examiners requires a flexible strategy. While EMCH, GREGORY S handles 1 busiest examiner pending action, the other pending matter is overseen by a different individual. Success in these 2 pending office actions depends on addressing the specific requirements of each of the 2 distinct art units involved in the process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EMCH, GREGORY S | 1 | 48.0% | +43.2% |
| DARRIGRAND, EMILY ANN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18141239 | IMMUNOGENICITY PREDICTION DEVICE, IMMUNOGENICITY PREDICTION METHOD AND COMPUTER PROGRAM FOR SYNTHETIC LONG PEPTIDE DESIGN | EMCH, GREGORY S | — |
| 17909866 | METHOD AND COMPUTER PROGRAM FOR PREDICTING NEOANTIGEN BY USING PEPTIDE SEQUENCE AND HLA ALLELE SEQUENCE | DARRIGRAND, EMILY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18141239 | IMMUNOGENICITY PREDICTION DEVICE, IMMUNOGENICITY PREDICTION METHOD AND COMPUTER PROGRAM FOR SYNTHETIC LONG PEPTIDE DESIGN | EMCH, GREGORY S | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18141239 | IMMUNOGENICITY PREDICTION DEVICE, IMMUNOGENICITY PREDICTION METHOD AND COMPUTER PROGRAM FOR SYNTHETIC LONG PEPTIDE DESIGN | EMCH, GREGORY S | 1678 | §101§103§112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 17909866 | METHOD AND COMPUTER PROGRAM FOR PREDICTING NEOANTIGEN BY USING PEPTIDE SEQUENCE AND HLA ALLELE SEQUENCE | DARRIGRAND, EMILY ANN | 1686 | §101§103§112 | Non-Final OA | — | Pending | Sep 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTheragen Bio Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Gregory S Emch has the most, with 1 of Theragen Bio Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
